Application Sponsors
ANDA 212421 | LAURUS GENERICS INC | |
Marketing Status
None (Tentative Approval) | 001 |
None (Tentative Approval) | 002 |
Application Products
001 | TABLET;ORAL | 10MG | 0 | EMPAGLIFLOZIN | EMPAGLIFLOZIN |
002 | TABLET;ORAL | 25MG | 0 | EMPAGLIFLOZIN | EMPAGLIFLOZIN |
FDA Submissions
UNKNOWN; | ORIG | 1 | TA | 2022-06-30 | STANDARD |
Submissions Property Types
CDER Filings
LAURUS GENERICS INC
cder:Array
(
[0] => Array
(
[ApplNo] => 212421
[companyName] => LAURUS GENERICS INC
[docInserts] => ["",""]
[products] => [{"drugName":"EMPAGLIFLOZIN","activeIngredients":"EMPAGLIFLOZIN","strength":"10MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"EMPAGLIFLOZIN","activeIngredients":"EMPAGLIFLOZIN","strength":"25MG","dosageForm":"TABLET;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"06\/30\/2022","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2022-06-30
)
)